ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR)
CUSIP: 04280A100
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 135,488,140
- Total 13F shares
- 99,701,045
- Share change
- +1,798,039
- Total reported value
- $1,874,384,692
- Put/Call ratio
- 94%
- Price per share
- $18.80
- Number of holders
- 267
- Value change
- +$32,738,534
- Number of buys
- 120
- Number of sells
- 125
Quarterly Holders Quick Answers
What is CUSIP 04280A100?
CUSIP 04280A100 identifies ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04280A100:
Top shareholders of ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
12%
|
15,835,912
|
$306,741,615 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
9%
|
12,229,055
|
$236,876,795 | — | 30 Sep 2024 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
6.6%
|
8,888,888
|
$172,177,761 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
4.7%
|
6,354,331
|
$123,083,391 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
4.5%
|
6,067,569
|
$117,528,805 | — | 30 Sep 2024 | |
| Slate Path Capital LP |
13F
|
Company |
3.6%
|
4,885,000
|
$94,622,450 | — | 30 Sep 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.6%
|
3,574,573
|
$69,240,000 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
2,964,119
|
$57,425,647 | — | 30 Sep 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
1.8%
|
2,458,778
|
$47,626,530 | — | 30 Sep 2024 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
1.6%
|
2,154,250
|
$41,727,821 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.6%
|
2,148,405
|
$41,614,606 | — | 30 Sep 2024 | |
| NORGES BANK |
13F
|
Company |
1.5%
|
2,044,662
|
$39,605,103 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.2%
|
1,605,766
|
$31,103,689 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.98%
|
1,332,765
|
$25,815,658 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.94%
|
1,272,901
|
$24,656,093 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.87%
|
1,177,577
|
$22,809,667 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.74%
|
1,006,935
|
$19,504,331 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.64%
|
866,399
|
$16,782,150 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.64%
|
865,794
|
$16,770,430 | — | 30 Sep 2024 | |
| Western Financial Corp/CA |
13F
|
Company |
0.61%
|
820,239
|
$15,888,029 | — | 30 Sep 2024 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
0.59%
|
795,813
|
$15,414,898 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.48%
|
645,604
|
$12,505,349 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.43%
|
578,760
|
$11,210,581 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.34%
|
463,880
|
$8,985,356 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
441,511
|
$8,552,069 | — | 30 Sep 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.3%
|
401,146
|
$7,770,198 | — | 30 Sep 2024 | |
| CenterBook Partners LP |
13F
|
Company |
0.29%
|
394,578
|
$7,642,976 | — | 30 Sep 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.29%
|
387,687
|
$7,509,495 | — | 30 Sep 2024 | |
| Javier San Martin |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
198,497
|
$7,417,833 | — | 04 Jan 2024 | |
| Hound Partners, LLC |
13F
|
Company |
0.28%
|
378,708
|
$7,335,574 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.27%
|
372,432
|
$7,213,979 | — | 30 Sep 2024 | |
| Altium Capital Management LLC |
13F
|
Company |
0.26%
|
355,000
|
$6,876,350 | — | 30 Sep 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.26%
|
350,000
|
$6,779,500 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.25%
|
335,314
|
$6,495,033 | — | 30 Sep 2024 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.25%
|
333,356
|
$6,457,106 | — | 30 Sep 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.24%
|
325,000
|
$6,295,250 | — | 30 Sep 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.23%
|
315,373
|
$6,108,785 | — | 30 Sep 2024 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.22%
|
300,366
|
$5,818,089 | — | 30 Sep 2024 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.22%
|
293,083
|
$5,677,018 | — | 30 Sep 2024 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.21%
|
290,994
|
$5,636,553 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
287,282
|
$5,564,652 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.2%
|
276,610
|
$5,357,935 | — | 30 Sep 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.2%
|
265,923
|
$5,150,929 | — | 30 Sep 2024 | |
| Capital International Investors |
13F
|
Company |
0.19%
|
255,871
|
$4,956,221 | — | 30 Sep 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.18%
|
247,598
|
$4,795,973 | — | 30 Sep 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.18%
|
242,875
|
$4,704,488 | — | 30 Sep 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0.18%
|
241,845
|
$4,684,537 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
231,300
|
$4,480,281 | — | 30 Sep 2024 | |
| SILVERCREST ASSET MANAGEMENT GROUP LLC |
13F
|
Company |
0.17%
|
224,889
|
$4,356,100 | — | 30 Sep 2024 | |
| WCM INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.16%
|
219,962
|
$4,326,653 | — | 30 Sep 2024 |
Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) as of Q4 2024
As of 31 Dec 2024,
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) was held by
267 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,701,045 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, STATE STREET CORP, Slate Path Capital LP, FMR LLC, GEODE CAPITAL MANAGEMENT, LLC, Siren, L.L.C., T. Rowe Price Investment Management, Inc., and NORGES BANK.
This page lists
267
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
267
Q4 2024 holders
267
Holder diff
0
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.